Pretreatment Nomogram That Predicts 5-Year Probability of Metastasis Following Three-Dimensional Conformal Radiation Therapy for Localized Prostate Cancer
- 15 December 2003
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (24) , 4568-4571
- https://doi.org/10.1200/jco.2003.05.046
Abstract
Purpose: There are several nomograms for the patient considering radiation therapy for clinically localized prostate cancer. Because of the questionable clinical implications of prostate-specific antigen (PSA) recurrence, its use as an end point has been criticized in several of these nomograms. The goal of this study was to create and to externally validate a nomogram for predicting the probability that a patient will develop metastasis within 5 years after three-dimensional conformal radiation therapy (CRT). Patients and Methods: We conducted a retrospective, nonrandomized analysis of 1,677 patients treated with three-dimensional CRT at Memorial Sloan-Kettering Cancer Center (MSKCC) from 1988 to 2000. Clinical parameters examined were pretreatment PSA level, clinical stage, and biopsy Gleason sum. Patients were followed until their deaths, and the time at which they developed metastasis was noted. A nomogram for predicting the 5-year probability of developing metastasis was constructed from the MSKCC co...Keywords
This publication has 15 references indexed in Scilit:
- A competing‐risks nomogram for sarcoma‐specific death following local recurrenceStatistics in Medicine, 2003
- Radical Radiation for Localized Prostate Cancer: Local Persistence of Disease Results in a Late Wave of MetastasesJournal of Clinical Oncology, 2002
- Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trialThe Lancet, 2002
- A STRUCTURED DEBATE: IMMEDIATE VERSUS DEFERRED ANDROGEN SUPPRESSION IN PROSTATE CANCER—EVIDENCE FOR DEFERRED TREATMENTJournal of Urology, 2001
- Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostateInternational Journal of Radiation Oncology*Biology*Physics, 2001
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1999
- Serum testosterone—A significant determinant of metastatic relapse for irradiated localized prostate cancerUrology, 1997
- The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvementInternational Journal of Radiation Oncology*Biology*Physics, 1994